Shareholder Information
Shares Issued
As at 28 July 2022, the number of shares in issue was 213,047,509.
Significant Shareholders
Shareholder | Number | Ordinary Shares % |
---|---|---|
Amati AIM VCT plc | 25,114,469 | 11.98 |
Bracco Imaging S.p.A. | 16,388,888 | 7.82 |
Hargreaves Lansdown | 13,434,964 | 6.41 |
Bastiaan Driehuys | 12,267,503 | 5.85 |
NUKEM Isotopes GmbH | 11,523,462 | 5.50 |
Chelverton Asset Management Ltd | 9,425,000 | 4.50 |
Tyndall Investment Management | 8,189,478 | 3.91 |
Canaccord Genuity Wealth Management (Inst) | 7,111,877 | 3.39 |
Director Shareholdings
Director | Number | Ordinary Shares % |
---|---|---|
Bastiaan Driehuys | 12,267,503 | 5.9 |
Richard Hullihen | 3,201,959 | 1.5 |
Jonathan Allis | 2,743,129 | 1.3 |
Cyrille Petit | 584,000 | 0.3 |
Kenneth West | 475,594 | 0.2 |
PDMR Notifications
Name |
Richard Hullihen |
Jonathan Allis |
Cyrille Petit |
Charles Osborne |
Kenneth West |
Bastiaan Driehuys |
Juergen Laucht |
Kiarash Emami |
Neil Wadehra |
Alexander Dusek |
Frank Schulkes |
Dan Brague |
Shares not in public hands
A total of 51.4% of the Company's securities are not in public hands.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Restrictions in transfer of AIM securities
There are no restrictions on the transfer of the company's ordinary shares.
UK City Code on Takeovers and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Other exchanges and trading platforms
Polarean Imaging Limited has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.
Shareholder Circulars
Page last updated: 28 July 2022
Latest News
-
FDA grants New Chemical Entity designation for XENOVIEW
01 February 2023
-
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized)
28 December 2022 -
Update on New Drug Application
30 September 2022
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts